How to buy Royalty Pharma stock

Royalty Pharma plc is a biotechnology business based in the US. Royalty Pharma shares (RPRX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Royalty Pharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Royalty Pharma. Find the stock by name or ticker symbol: RPRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Royalty Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Royalty Pharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Royalty Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Royalty Pharma share price

Use our graph to track the performance of RPRX stocks over time.

Royalty Pharma shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$27.6887 - USD$55.8717
50-day moving average	USD$49.0342
200-day moving average	USD$43.9411
Wall St. target price	USD$52.14
PE ratio	22.6036
Dividend yield	USD$0.68 (1.42%)
Earnings per share (TTM)	USD$-0.621

Buy Royalty Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Royalty Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Royalty Pharma plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Royalty Pharma financials

Revenue TTM	USD$2.1 billion
Operating margin TTM	75.17%
Gross profit TTM	USD$1.9 billion
Return on assets TTM	0%
Return on equity TTM	21.36%
Profit margin	45.95%
Book value	$-0.033
Market capitalisation	USD$29.3 billion

TTM: trailing 12 months

Shorting Royalty Pharma shares

There are currently 8.7 million Royalty Pharma shares held short by investors – that's known as Royalty Pharma's "short interest". This figure is 3.3% down from 9.0 million last month.

There are a few different ways that this level of interest in shorting Royalty Pharma shares can be evaluated.

Royalty Pharma's "short interest ratio" (SIR)

Royalty Pharma's "short interest ratio" (SIR) is the quantity of Royalty Pharma shares currently shorted divided by the average quantity of Royalty Pharma shares traded daily (recently around 3.4 million). Royalty Pharma's SIR currently stands at 2.6. In other words for every 100,000 Royalty Pharma shares traded daily on the market, roughly 2600 shares are currently held short.

To gain some more context, you can compare Royalty Pharma's short interest ratio against those of similar companies.

• Alexion Pharmaceuticals (ALXN.US): 1.43
• Cigna Corporation (CI.US): 2.51
• Gilead Sciences (GILD.US): 2.16
• Novartis (NVS.US): 2.41

However Royalty Pharma's short interest can also be evaluated against the total number of Royalty Pharma shares, or, against the total number of tradable Royalty Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Royalty Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Royalty Pharma shares in existence, roughly 10 shares are currently held short) or 0.0305% of the tradable shares (for every 100,000 tradable Royalty Pharma shares, roughly 31 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Royalty Pharma.

Find out more about how you can short Royalty Pharma stock.

Royalty Pharma overview

Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.

Frequently asked questions

• What percentage of Royalty Pharma is owned by insiders or institutions?

  Currently 17.496% of Royalty Pharma shares are held by insiders and 44.419% by institutions.

• When does the fiscal year end for Royalty Pharma?

  Royalty Pharma's fiscal year ends in December.

• Where is Royalty Pharma based?

  Royalty Pharma's address is: 110 East 59th Street, New York, NY, United States, 10022

• What is Royalty Pharma's ISIN number?

  Royalty Pharma's international securities identification number is: GB00BMVP7Y09

• What is Royalty Pharma's CUSIP number?

  Royalty Pharma's Committee on Uniform Securities Identification Procedures number is: 76028H100